UNCY Unicycive Therapeutics Inc Forecast, Technical & Fundamental Analysis
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease... Show more
UNCY is expected to report earnings to fall 34.81% to -35 cents per share on November 18
Q3'26
Est.
$-0.35
Q1'26
Missed
by $0.66
Q4'25
Missed
by $0.65
Q3'25
Missed
by $0.26
Q2'25
Missed
by $1.43
The last earnings report on May 12 showed earnings per share of -54 cents, missing the estimate of 11 cents. With 411.46K shares outstanding, the current market capitalization sits at 140.67M.
A.I.dvisor indicates that over the last year, UNCY has been loosely correlated with NVCT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if UNCY jumps, then NVCT could also see price increases.
UNCY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on August 31, 2026
UNCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where UNCY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UNCY advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNCY as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for UNCY turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for UNCY moved below the 200-day moving average on August 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.641) is normal, around the industry mean (20.183). P/E Ratio (0.000) is within average values for comparable stocks, (27.671). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.520). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (39.216) is also within normal values, averaging (441.890).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UNCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
